Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

Eric Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Kathy Williams, Ian Rosenthal, Richard J. O'Brien, Andrew A. Vernon, Richard E Chaisson, William Ramses Bishai, Jacques H. Grosset

Research output: Contribution to journalArticle

Abstract

In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.

Original languageEnglish (US)
Pages (from-to)1131-1134
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume170
Issue number10
DOIs
StatePublished - Nov 15 2004
Externally publishedYes

Fingerprint

Pyrazinamide
Tuberculosis
Rifampin
Isoniazid
Recurrence
moxifloxacin
Therapeutics
Lung

Keywords

  • Fluoroquinolone
  • Mouse
  • Moxifloxacin
  • Pyrazinamide
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. / Nuermberger, Eric; Yoshimatsu, Tetsuyuki; Tyagi, Sandeep; Williams, Kathy; Rosenthal, Ian; O'Brien, Richard J.; Vernon, Andrew A.; Chaisson, Richard E; Bishai, William Ramses; Grosset, Jacques H.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 170, No. 10, 15.11.2004, p. 1131-1134.

Research output: Contribution to journalArticle

Nuermberger, Eric ; Yoshimatsu, Tetsuyuki ; Tyagi, Sandeep ; Williams, Kathy ; Rosenthal, Ian ; O'Brien, Richard J. ; Vernon, Andrew A. ; Chaisson, Richard E ; Bishai, William Ramses ; Grosset, Jacques H. / Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. In: American Journal of Respiratory and Critical Care Medicine. 2004 ; Vol. 170, No. 10. pp. 1131-1134.
@article{4edc40398f31418caffad69802964876,
title = "Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis",
abstract = "In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.",
keywords = "Fluoroquinolone, Mouse, Moxifloxacin, Pyrazinamide, Tuberculosis",
author = "Eric Nuermberger and Tetsuyuki Yoshimatsu and Sandeep Tyagi and Kathy Williams and Ian Rosenthal and O'Brien, {Richard J.} and Vernon, {Andrew A.} and Chaisson, {Richard E} and Bishai, {William Ramses} and Grosset, {Jacques H.}",
year = "2004",
month = "11",
day = "15",
doi = "10.1164/rccm.200407-885OC",
language = "English (US)",
volume = "170",
pages = "1131--1134",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

AU - Nuermberger, Eric

AU - Yoshimatsu, Tetsuyuki

AU - Tyagi, Sandeep

AU - Williams, Kathy

AU - Rosenthal, Ian

AU - O'Brien, Richard J.

AU - Vernon, Andrew A.

AU - Chaisson, Richard E

AU - Bishai, William Ramses

AU - Grosset, Jacques H.

PY - 2004/11/15

Y1 - 2004/11/15

N2 - In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.

AB - In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.

KW - Fluoroquinolone

KW - Mouse

KW - Moxifloxacin

KW - Pyrazinamide

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=8444223157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444223157&partnerID=8YFLogxK

U2 - 10.1164/rccm.200407-885OC

DO - 10.1164/rccm.200407-885OC

M3 - Article

C2 - 15306535

AN - SCOPUS:8444223157

VL - 170

SP - 1131

EP - 1134

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -